Friday 6 November 2026
Export AMPH’s income statement to Excel — free account
Amphastar Pharmaceuticals, Inc.
AMPH Healthcare Drug Manufacturers Specialty & Generic
Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024.
- Revenue
- +8.22%
- EPS
- +134.2%
- Free cash flow
- −29.4%
- Total debt
- +0.57%
Quarter to September 2026, against a year earlier
27.59
0.43
−1.53%
Follow AMPH
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
6 | 5 | 6 | 6 |
+8 more TTM periods Free account |
| 12.44% | 10.30% | 10.39% | 12.90% | ||
| 5.86% | 4.68% | 4.84% | 6.12% | ||
ROIC |
6.12% | 6.57% | 6.69% | 7.88% | |
Return on Tangible Assets |
13.48% | 11.49% | 10.20% | 12.44% | |
Average Days of Receivables |
0.00 | 73.74 | 79.76 | 81.49 | |
Free Cash Flow per Share |
3.26 | 3.50 | 2.98 | 2.54 | |
Free Cash Flow |
139.02 | 152.89 | 135.19 | 118.83 | |
Capital Expenditures |
(36.31) | (31.72) | (33.69) | (37.28) | |
| Other line items | |||||
Cash ROIC |
9.74% | 9.14% | 8.05% | 7.05% | |
Accounts Receivable Turnover |
0.00 | 5.18 | 4.76 | 4.82 | |
Accounts Payable Turnover |
2.21 | 1.83 | 2.31 | 2.38 | |
Inventory Turnover |
2.20 | 2.06 | 2.13 | 2.20 | |
Average Days of Payables |
154.64 | 240.24 | 146.89 | 148.83 | |
Days of Inventory on Hand |
160.02 | 171.94 | 163.73 | 177.46 | |
Tax Rate |
(0.24) | (0.23) | (0.23) | (0.21) | |
Research and Development Expense of Revenue |
12.38% | 12.95% | 12.84% | 11.92% | |
Selling, General and Administrative Expense of Revenue |
15.70% | 19.08% | 18.31% | 18.03% | |
Share Based Compensation of Revenue |
3.97% | 3.95% | 3.91% | 3.79% | |
Interest Coverage |
5.25 | 4.37 | 4.53 | 5.51 | |
Operating CF/Net income |
1.77 | 2.35 | 2.13 | 1.59 | |
Depreciation/Fixed assets |
0.00 | 0.19 | 0.20 | 0.19 | |
Capex/Depreciation |
0.00 | (0.52) | (0.55) | (0.62) | |
Revenue per Share |
17.52 | 16.73 | 15.90 | 15.40 | |
Operating CF per Share |
4.12 | 4.23 | 3.73 | 3.34 | |
Capex per Share |
(0.85) | (0.73) | (0.74) | (0.80) | |
Capex to Sales |
0.05 | 0.04 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 5 Nov 2026